Thursday, November 16, 2017 -- The FDA has approved obinutuzumab (Gazyva) in combination with chemotherapy, followed by obinutuzumab alone, for the first-line treatment of patients with advanced follicular lymphoma.
Friday, November 17, 2017 -- Obinutuzumab (Gazyva) has been approved by the FDA in combination with chemotherapy, followed by obinutuzumab alone, for the first-line treatment of patients with advanced follicular lymphoma, according to Genentech, the manufacturer of the therapy.
Wednesday, November 15, 2017 -- Purpose: B-cell lymphomas must acquire resistance to apoptosis during their development. We recently discovered BCLW, an antiapoptotic BCL2 family member thought only to contribute to spermatogenesis, was overexpressed in diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma. To gain insight into the contribution of BCLW to B-cell lymphomas and its potential to confer resistance to BCL2 inhibitors, we investigated the expression of BCLW and the other antiapoptotic BCL2 family members in six different B-cell lymphomas. Experimental Design: We performed a large-scale gene expression analysis of datasets comprising approximately 2,300 lymphoma patient samples, including non-Hodgkin and Hodgkin lymphomas as well as indolent and aggressive lymphomas. Data were validated experimentally with qRT-PCR and IHC. Results: We report BCLW is significantly overexpressed
Thursday, November 16, 2017 -- Survival outcome for elderly patients with newly diagnosed diffuse large B-cell lymphoma remains suboptimal in the rituximab era. In this systematic review, we summarize available evidence relevant to the inclusion of anthracycline in upfront chemoimmunotherapy for these elderly patients and highlight the need of prospective clinical trials. With limited prospective data, we find that pretreatment comprehensive geriatric assessment accurately predicts survival and treatment-related toxicities, suggesting its potential role in guiding overall treatment decision-making.
Thursday, November 16, 2017 -- Identification of prognostic factors for patients with relapsed/refractory Hodgkin lymphoma (HL) is essential for optimizing therapy with risk-adapted approaches. In our phase 2 study of positron emission tomography (PET)–adapted salvage therapy with brentuximab vedotin (BV) and augmented ifosfamide, carboplatin, and etoposide (augICE), we assessed clinical factors, quantitative PET assessments, and cytokine and chemokine values. Transplant-eligible patients with relapsed/refractory HL received 2 (cohort 1) or 3 (cohort 2) cycles of weekly BV; PET-negative patients (Deauville score ≤2) proceeded to autologous stem cell transplantation (ASCT) whereas PET-positive patients received augICE before ASCT. Serum cytokine and chemokine levels were measured at baseline and after BV. Metabolic tumor volume (MTV) and total lesion glycolysis were measured at baseline, after BV, and after augICE.
Thursday, November 16, 2017 -- The approval is based on results from the Phase 3 GALLIUM study.
Thursday, November 16, 2017 -- In this analysis, researchers measured the impact and effectiveness of supportive treatments for moderate to severe anemia in patients with lymphoma or multiple myeloma, based on patient-reported outcomes.
Friday, November 17, 2017 -- NewsWith the approval, Gazyva is available in the United States for three different indications across two common types of blood cancer. Follicular lymphoma is incurable and becomes harder to treat each time it returns. Contributed Author: GenentechTopics: Drug Development
Thursday, November 16, 2017 -- ZURICH (Reuters) - The U.S. Food and Drug Administration on Thursday expanded approvals for Roche's Gazyva to include previously untreated follicular lymphoma, bolstering the Swiss drugmaker's efforts to strengthen its portfolio of blood cancer medicines.